FR3039166A1 - - Google Patents

Download PDF

Info

Publication number
FR3039166A1
FR3039166A1 FR1557020A FR1557020A FR3039166A1 FR 3039166 A1 FR3039166 A1 FR 3039166A1 FR 1557020 A FR1557020 A FR 1557020A FR 1557020 A FR1557020 A FR 1557020A FR 3039166 A1 FR3039166 A1 FR 3039166A1
Authority
FR
France
Prior art keywords
cells
population
platelets
mks
cd41dim
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR1557020A
Other languages
English (en)
French (fr)
Other versions
FR3039166B1 (fr
Inventor
Catherine Strassel
Christian Gachet
Francois Lanza
Nathalie Brouard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Strasbourg
Original Assignee
Etablissement Francais du Sang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1557020A priority Critical patent/FR3039166B1/fr
Application filed by Etablissement Francais du Sang filed Critical Etablissement Francais du Sang
Priority to CN201680047758.8A priority patent/CN107922924B/zh
Priority to EP16742302.9A priority patent/EP3334822B1/en
Priority to AU2016296920A priority patent/AU2016296920B2/en
Priority to US15/747,023 priority patent/US11236303B2/en
Priority to PCT/EP2016/067594 priority patent/WO2017013262A1/en
Priority to JP2018503184A priority patent/JP7068162B6/ja
Priority to CA2993596A priority patent/CA2993596A1/en
Publication of FR3039166A1 publication Critical patent/FR3039166A1/fr
Application granted granted Critical
Publication of FR3039166B1 publication Critical patent/FR3039166B1/fr
Priority to JP2021121618A priority patent/JP2021177774A/ja
Priority to US17/547,444 priority patent/US20220135946A1/en
Priority to US18/820,807 priority patent/US20240417686A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0644—Platelets; Megakaryocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/19—Platelets; Megacaryocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/36—Lipids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2309—Interleukin-9 (IL-9)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/60—Transcription factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
    • C12N2502/1352—Mesenchymal stem cells
    • C12N2502/1358—Bone marrow mesenchymal stem cells (BM-MSC)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR1557020A 2015-07-23 2015-07-23 Progeniteurs de megacaryocytes cd34+cd41dim et leurs utilisations pour produire des plaquettes et/ou des mk portant des proplaquettes Active FR3039166B1 (fr)

Priority Applications (11)

Application Number Priority Date Filing Date Title
FR1557020A FR3039166B1 (fr) 2015-07-23 2015-07-23 Progeniteurs de megacaryocytes cd34+cd41dim et leurs utilisations pour produire des plaquettes et/ou des mk portant des proplaquettes
CA2993596A CA2993596A1 (en) 2015-07-23 2016-07-22 Cd34+cd41dim megakaryocytes progenitors and uses thereof for producing proplatelet-bearing mks and/or platelets
AU2016296920A AU2016296920B2 (en) 2015-07-23 2016-07-22 CD34+CD41dim megakaryocytes progenitors and uses thereof for producing proplatelet-bearing MKs and/or platelets
US15/747,023 US11236303B2 (en) 2015-07-23 2016-07-22 CD34+CD41DIM megakaryocytes progenitors and uses thereof for producing proplatelet-bearing MKs and/or platelets
PCT/EP2016/067594 WO2017013262A1 (en) 2015-07-23 2016-07-22 Cd34+cd41dim megakaryocytes progenitors and uses thereof for producing proplatelet-bearing mks and/or platelets
JP2018503184A JP7068162B6 (ja) 2015-07-23 2016-07-22 Ｃｄ３４＋ｃｄ４１ｄｉｍ巨核球前駆細胞及び血小板前駆細胞を有するｍｋ及び／又はその血小板を製造するためのその使用。
CN201680047758.8A CN107922924B (zh) 2015-07-23 2016-07-22 巨核细胞祖细胞及其产生带有前血小板的mk和/或血小板的应用
EP16742302.9A EP3334822B1 (en) 2015-07-23 2016-07-22 Cd34+cd41dim megakaryocytes progenitors and uses thereof for producing proplatelet-bearing mks and/or platelets
JP2021121618A JP2021177774A (ja) 2015-07-23 2021-07-26 Ｃｄ３４＋ｃｄ４１ｄｉｍ巨核球前駆細胞及び血小板前駆細胞を有するｍｋ及び／又はその血小板を製造するためのその使用。
US17/547,444 US20220135946A1 (en) 2015-07-23 2021-12-10 Cd34+cd41dim megakaryocytes progenitors and uses thereof for producing proplatelet-bearing mks and/or platelets
US18/820,807 US20240417686A1 (en) 2015-07-23 2024-08-30 Cd34+cd41dim megakaryocytes progenitors and uses thereof for producing proplatelet-bearing mks and/or platelets

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1557020 2015-07-23
FR1557020A FR3039166B1 (fr) 2015-07-23 2015-07-23 Progeniteurs de megacaryocytes cd34+cd41dim et leurs utilisations pour produire des plaquettes et/ou des mk portant des proplaquettes

Publications (2)

Publication Number Publication Date
FR3039166A1 true FR3039166A1 (enExample) 2017-01-27
FR3039166B1 FR3039166B1 (fr) 2018-10-26

Family

ID=55072774

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1557020A Active FR3039166B1 (fr) 2015-07-23 2015-07-23 Progeniteurs de megacaryocytes cd34+cd41dim et leurs utilisations pour produire des plaquettes et/ou des mk portant des proplaquettes

Country Status (8)

Country Link
US (3) US11236303B2 (enExample)
EP (1) EP3334822B1 (enExample)
JP (2) JP7068162B6 (enExample)
CN (1) CN107922924B (enExample)
AU (1) AU2016296920B2 (enExample)
CA (1) CA2993596A1 (enExample)
FR (1) FR3039166B1 (enExample)
WO (1) WO2017013262A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3101885A1 (fr) 2019-10-11 2021-04-16 Etablissement Français Du Sang Systeme pour la liberation de plaquettes et procede de liberation de plaquettes

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3039166B1 (fr) * 2015-07-23 2018-10-26 Institut National De La Sante Et De La Recherche Medicale Progeniteurs de megacaryocytes cd34+cd41dim et leurs utilisations pour produire des plaquettes et/ou des mk portant des proplaquettes
MX2020007071A (es) 2018-01-05 2020-11-11 Platelet Biogenesis Inc Composiciones y metodos para producir megacariocitos.
WO2020006539A1 (en) 2018-06-29 2020-01-02 Platelet Biogenesis, Inc. Compositions for drug delivery and methods of use thereof
CN115868454B (zh) * 2022-12-23 2025-09-02 中国医学科学院血液病医院(中国医学科学院血液学研究所) 基于免疫缺陷小鼠移植检测人巨核偏向造血干细胞功能方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014138485A1 (en) * 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004024875A2 (en) * 2002-09-13 2004-03-25 The Board Of Trustees Of The Leland Stanford Junior University Mammalian megakaryocyte progenitor cell
WO2009119105A1 (ja) 2008-03-28 2009-10-01 国立大学法人東京大学 ＧＰＩｂα＋ＧＰＶ＋ＧＰＶＩ＋血小板のインビトロ調製法
WO2012129109A2 (en) 2011-03-18 2012-09-27 New York Blood Center, Inc. Megakaryocyte and platelet production from stem cells
US9920295B2 (en) 2012-02-21 2018-03-20 The Trustees Of The University Of Pennsylvania Bioreactor for isolation of rare cells and methods of use
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
GB201220937D0 (en) * 2012-11-21 2013-01-02 Airbus Uk Ltd Modular structural assembly
FR3039166B1 (fr) * 2015-07-23 2018-10-26 Institut National De La Sante Et De La Recherche Medicale Progeniteurs de megacaryocytes cd34+cd41dim et leurs utilisations pour produire des plaquettes et/ou des mk portant des proplaquettes

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014138485A1 (en) * 2013-03-08 2014-09-12 Irm Llc Ex vivo production of platelets from hematopoietic stem cells and the product thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BRUNO S ET AL: "IN VITRO AND IN VIVO MEGAKARYOCYTE DIFFERENTIATION OF FRESH AND EX-VIVO EXPANDED CORD BLOOD CELLS: RAPID AND TRANSIENT MEGAKARYOCYTE RECONSTITUTION", HAEMATOLOGICA, THE HEMATOLOGY JOURNAL : OFFICIAL ORGAN OF THE EUROPEAN HEMATOLOGY ASSOCIATION, FONDAZIONE FERRATA STORTI, IT, vol. 88, no. 4, 1 April 2003 (2003-04-01), pages 379 - 387, XP008077211, ISSN: 0390-6078 *
L. CHENG ET AL: "Human Mesenchymal Stem Cells Support Megakaryocyte and Pro-Platelet Formation From CD34 Hematopoietic Progenitor Cells", J. CELL. PHYSIOL., 1 January 2000 (2000-01-01), pages 58 - 69, XP055135575, Retrieved from the Internet <URL:http://onlinelibrary.wiley.com/store/10.1002/(SICI)1097-4652(200007)184:1<58::AID-JCP6>3.0.CO;2-B/asset/6_ftp.pdf?v=1&t=hz2oa8j7&s=937389292d034b0fb93b3f66ff525d5eaad37f5c> [retrieved on 20140820] *
LIU B ET AL: "A potential activity of valproic acid in the stimulation of interleukin-3-mediated megakaryopoiesis and erythropoiesis", EXPERIMENTAL HEMATOLOGY, ELSEVIER INC, US, vol. 38, no. 8, 1 August 2010 (2010-08-01), pages 685 - 695, XP027136852, ISSN: 0301-472X, [retrieved on 20100408] *
MCGRATH KATHLEEN E ED - SANCHEZ ANA ET AL: "Utilization of imaging flow cytometry to define intermediates of megakaryopoiesis in vivo and in vitro", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 423, 17 March 2015 (2015-03-17), pages 45 - 51, XP029247220, ISSN: 0022-1759, DOI: 10.1016/J.JIM.2015.03.002 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3101885A1 (fr) 2019-10-11 2021-04-16 Etablissement Français Du Sang Systeme pour la liberation de plaquettes et procede de liberation de plaquettes

Also Published As

Publication number Publication date
JP2018519845A (ja) 2018-07-26
CA2993596A1 (en) 2017-01-26
EP3334822A1 (en) 2018-06-20
US20240417686A1 (en) 2024-12-19
EP3334822B1 (en) 2025-10-15
US20180216068A1 (en) 2018-08-02
US11236303B2 (en) 2022-02-01
JP2021177774A (ja) 2021-11-18
JP7068162B2 (ja) 2022-05-16
AU2016296920A1 (en) 2018-02-15
WO2017013262A1 (en) 2017-01-26
CN107922924A (zh) 2018-04-17
US20220135946A1 (en) 2022-05-05
FR3039166B1 (fr) 2018-10-26
CN107922924B (zh) 2022-01-11
AU2016296920B2 (en) 2022-05-26
JP7068162B6 (ja) 2023-12-20

Similar Documents

Publication Publication Date Title
Quirici et al. Isolation of bone marrow mesenchymal stem cells by anti-nerve growth factor receptor antibodies
US8318489B2 (en) Prostacyclin directed differentiation of cardiomyocytes from human embryonic stem cells
US20240417686A1 (en) Cd34+cd41dim megakaryocytes progenitors and uses thereof for producing proplatelet-bearing mks and/or platelets
Grayson et al. Hypoxia enhances proliferation and tissue formation of human mesenchymal stem cells
Grisendi et al. GMP-manufactured density gradient media for optimized mesenchymal stromal/stem cell isolation and expansion
KR20150126943A (ko) 규정된 조건하에서 인간 만능성 줄기 세포의 조혈내피세포 분화를 위한 방법 및 재료
JP6954844B2 (ja) 造血幹細胞を培養するため及び／又は造血幹細胞を前駆体へ分化させるための方法及びその使用
US20250297222A1 (en) Xeno-free generation of tissue-specific progenitor cells
JP2011501960A (ja) 月経血幹細胞と共に臍帯血由来細胞を共培養する方法
KR102320682B1 (ko) 요유래 줄기세포 배양을 위한 배지조성물 및 이를 이용한 요유래 줄기세포의 배양방법
JP7758411B1 (ja) 間葉系幹細胞培養物の製造方法
KR101149007B1 (ko) 생착능이 증가된 조혈줄기세포의 제조방법
RU2722669C1 (ru) Способ получения ассоциатов гемопоэтических и стромальных клеток-предшественников, способных подавлять активацию и пролиферацию аллогенных лимфоцитов
JP5856029B2 (ja) 間葉系幹細胞を未分化増殖させる方法、および間葉系幹細胞を濃縮する方法
WO2025253985A1 (ja) 間葉系幹細胞培養物の製造方法
JP2025066198A (ja) 造血幹細胞移植における移植前処理を受けた患者を処置する方法および当該方法に用いるための組成物
Willemze et al. Preferential chondrogenic differentiation potential of human bone marrow-derived mesenchymal stem cells
EA026459B1 (ru) Способ экспансии ex vivo кроветворных клеток человека

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

EXTE Extension to a french territory

Extension state: PF

PLSC Publication of the preliminary search report

Effective date: 20170127

PLFP Fee payment

Year of fee payment: 3

TQ Partial transmission of property

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERC, FR

Effective date: 20180319

Owner name: UNIVERSITE DE STRASBOURG, FR

Effective date: 20180319

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

PLFP Fee payment

Year of fee payment: 11